Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078535" target="_blank" >RIV/65269705:_____/23:00078535 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00133687
Result on the web
<a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186" target="_blank" >https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300186" target="_blank" >10.2807/1560-7917.ES.2023.28.47.2300186</a>
Alternative languages
Result language
angličtina
Original language name
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Original language description
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients >= 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine >= 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged >= 80 years. During the Delta period, among SARI patients >= 20 years with symptom onset >= 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) >= 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; >= 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Eurosurveillance
ISSN
1025-496X
e-ISSN
1560-7917
Volume of the periodical
28
Issue of the periodical within the volume
47
Country of publishing house
SE - SWEDEN
Number of pages
16
Pages from-to
2300186
UT code for WoS article
001117609400005
EID of the result in the Scopus database
2-s2.0-85177867806